Eli Lilly's experimental pill, orforglipron, shows promise in treating obesity, helping participants lose an average of 12.4 kg over 72 weeks. Unlike other GLP-1 drugs that require injections, this pill offers a convenient alternative. The company plans to seek regulatory approval soon. While weight loss is slightly less than some competitors, the ease of use may increase demand. Side effects are mostly gastrointestinal. The findings are seen as a positive advancement in obesity treatment.